<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644446</url>
  </required_header>
  <id_info>
    <org_study_id>DC-2016-2725</org_study_id>
    <nct_id>NCT03644446</nct_id>
  </id_info>
  <brief_title>Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure</brief_title>
  <acronym>PREVALENT</acronym>
  <official_title>Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the dosage of bisoprolol plasma residual concentrations in chronic heart
      failure with mild to reduced ejection fraction adult patients by dose and renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical relevance of bisoprolol plasma residual concentration in the management of HF
      medical therapy and the impact of renal function on reaching the maximum tolerated dose has
      never been studied. The investigators will perform an observational study to answer this
      issue.

      In this study, there will be no changes of the doses of bisoprolol, whatever the bisoprolol
      plasma concentration, with the exception of vital threatening concentrations. This study is a
      pilot study.

      Participants will be consecutive ambulatory chronic heart failure patients followed at the
      CHU de Caen, treated with maximum tolerated dose of bisoprolol with mild to reduced ejection
      fraction. Participants can benefit of the other heart failure recommended treatment at the
      exception of ivabradine that would confound the bisoprolol effect on heart rate. Participants
      will be subsequently studied by renal function.

      Patients will be followed at one year with the electronic health record of the CHU de Caen
      for clinical events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">November 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Bisoprolol residual plasma concentration by dose and renal function</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Bisoprolol plasma residual concentrations will be performed by liquid chromatography with tandem mass spectrometry (LC-MS/MS) with simple precipitation of proteins with acetonitrile, as described by Liu et al. The quantification will be in positive mode by multiple reaction monitoring with the following transitions: 326 to 116 for bisoprolol and 256 to 167 for diphenhydramine (control). Bisoprolol concentrations will be expressed in µg/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at the time of inclusion</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Heart rate in beats per minute (bpm). Heart rate will be studied as a continous outcome and as a dichotomous outcome for efficacy. The efficacy parameter cutoff is a heart rate &lt; 70bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at the time of inclusion</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Systolic and diastolic blood pressure (in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at the time of inclusion</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Tolerance : presence of any new symptom that requires a dose lowering or discontinuation of bisoprolol (dichotomous outcome) or symptomatic orthostatic hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at the time of inclusion</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Tolerance : presence of a symptomatic orthostatic hypotension (dichotomous outcome) that is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within three minutes of standing when compared with blood pressure from the sitting or supine position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological assessment</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Routine biological evaluation : creatinine (in µmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological assessment</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Routine biological evaluation : Brain Natriuretic Peptide (in pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological assessment</measure>
    <time_frame>At the time of inclusion</time_frame>
    <description>Galectin-3 (in ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes at one year</measure>
    <time_frame>At one year follow-up</time_frame>
    <description>Heart failure symptoms worsening (dichotomous variable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes at one year</measure>
    <time_frame>At one year follow-up</time_frame>
    <description>Hospitalization for heart failure (dichotomous variable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes at one year</measure>
    <time_frame>At one year follow-up</time_frame>
    <description>Death from any cause (dichotomous variable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes at one year</measure>
    <time_frame>At one year follow-up</time_frame>
    <description>Bisoprolol dose modification (categorical variable : dose increased, dose decreased, dose unchanged and quantitative analysis of mean change between bisoprolol inclusion dose and bisoprolol dose at one year).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Bisoprolol 5mg</arm_group_label>
    <description>Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction &lt; 50%. Consecutive patients at the CHU de Caen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol 7.5mg</arm_group_label>
    <description>Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction &lt; 50%. Consecutive patients at the CHU de Caen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol 10mg</arm_group_label>
    <description>Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction &lt; 50%. Consecutive patients at the CHU de Caen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bisoprolol plasma residual concentration dosage</intervention_name>
    <description>Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance &lt; 30mL/min, mild altered between 30-60mL/min, normal &gt; 60mL/min as estimated by the CKD-EPI formula)</description>
    <arm_group_label>Bisoprolol 10mg</arm_group_label>
    <arm_group_label>Bisoprolol 5mg</arm_group_label>
    <arm_group_label>Bisoprolol 7.5mg</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      One blood sample for each patient at the time of inclusion.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive ambulatory chronic HFrEF patients followed at the CHU de Caen, treated with
        maximum tolerated dose of bisoprolol. Patients can benefit of other HFrEF recommended
        treatment at the exception of ivabradine that would confound the bisoprolol effect on heart
        rate. Patients will be subsequently studied by renal function (altered if creatinine
        clearance &lt; 30mL/min, mild altered between 30-60mL/min, normal &gt; 60mL/min as estimated by
        the CKD-EPI formula) and bisoprolol dose (5, 7.5 or 10mg).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive ambulatory patients with chronic heart failure with mild to reduced
             ejection fraction (LVEF &lt; 50%) at the CHU de Caen

          -  Aged 18 y.o. or older

          -  With a stable heart failure (see exclusion criteria)

          -  At the maximum tolerated dose of bisoprolol for at least one week (maximum dose
             reached without adverse tolerance event: orthostatic hypotension, symptomatic
             bradycardia, fatigue related to the treatment)

        Exclusion Criteria:

          -  Unstable HF, that are patients who presented in the last 3 months before inclusion an
             hospitalization for any cardiovascular event including HF, new onset or worsening of
             HF or coronary artery disease symptoms

          -  Patient refusing to participate

          -  Patients with a non maximum tolerated dose of bisoprolol

          -  Patients with ivabradine intakes

          -  Body weight &lt; 60kg or &gt; 100kg

          -  Severe liver insufficiency

          -  Pregnancy

          -  Liberty deprived patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandre Joachim</name>
      <address>
        <city>Caen</city>
        <state>Basse Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Alexandre, MD</last_name>
      <phone>+33231064670</phone>
      <email>alexandre-j@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Epidemiology, aetiology, and prognosis of heart failure -- McMurray and Stewart 83 (5): 596 -- Heart [Internet]. [cited 2016 May 3];Available from: http://heart.bmj.com/content/83/5/596.short</citation>
  </reference>
  <reference>
    <citation>Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007 Sep;93(9):1137-46. Review.</citation>
    <PMID>17699180</PMID>
  </reference>
  <reference>
    <citation>Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001 Jun;3(3):315-22.</citation>
    <PMID>11378002</PMID>
  </reference>
  <reference>
    <citation>Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):573-80. doi: 10.1161/CIRCOUTCOMES.110.957571. Epub 2010 Oct 5.</citation>
    <PMID>20923990</PMID>
  </reference>
  <reference>
    <citation>Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009 Feb 3;119(4):515-23. doi: 10.1161/CIRCULATIONAHA.108.812172. Epub 2009 Jan 19.</citation>
    <PMID>19153268</PMID>
  </reference>
  <reference>
    <citation>Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17. Review. Erratum in: Eur Heart J. 2010 Apr;12(4):416. Dosage error in article text. Eur Heart J. 2010 Mar;31(5):624. Dosage error in article text.</citation>
    <PMID>18799522</PMID>
  </reference>
  <reference>
    <citation>Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28;109(10):1176-94. doi: 10.1161/CIRCRESAHA.111.245092.</citation>
    <PMID>22034480</PMID>
  </reference>
  <reference>
    <citation>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13.</citation>
    <PMID>10023943</PMID>
  </reference>
  <reference>
    <citation>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7.</citation>
    <PMID>10376614</PMID>
  </reference>
  <reference>
    <citation>Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 8;283(10):1295-302.</citation>
    <PMID>10714728</PMID>
  </reference>
  <reference>
    <citation>Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9.</citation>
    <PMID>12390947</PMID>
  </reference>
  <reference>
    <citation>Pasternak B, Mattsson A, Svanström H, Hviid A. Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure. Int J Cardiol. 2015;190:4-6. doi: 10.1016/j.ijcard.2015.03.441. Epub 2015 Apr 18.</citation>
    <PMID>25912106</PMID>
  </reference>
  <reference>
    <citation>Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Piña IL, Whellan D, O'Connor CM. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012 Jul 17;60(3):208-15. doi: 10.1016/j.jacc.2012.03.023. Epub 2012 May 2.</citation>
    <PMID>22560018</PMID>
  </reference>
  <reference>
    <citation>Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O'Connor CM. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. JACC Heart Fail. 2016 Feb;4(2):109-115. doi: 10.1016/j.jchf.2015.09.002. Epub 2015 Oct 28.</citation>
    <PMID>26519996</PMID>
  </reference>
  <reference>
    <citation>Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008 Dec 1;102(11):1524-9. doi: 10.1016/j.amjcard.2008.07.045. Epub 2008 Sep 6.</citation>
    <PMID>19026308</PMID>
  </reference>
  <reference>
    <citation>Düngen HD, Apostolović S, Inkrot S, Tahirović E, Krackhardt F, Pavlović M, Putniković B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R; CIBIS-ELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol. 2008 Sep;97(9):578-86. doi: 10.1007/s00392-008-0681-6. Epub 2008 Jun 9.</citation>
    <PMID>18542839</PMID>
  </reference>
  <reference>
    <citation>Gelbrich G, Edelmann F, Inkrot S, Lainscak M, Apostolovic S, Neskovic AN, Waagstein F, Loeffler M, Anker SD, Dietz R, Düngen HD; CIBIS-ELD investigators. Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int J Cardiol. 2012 Feb 23;155(1):160-6. doi: 10.1016/j.ijcard.2011.11.018. Epub 2011 Nov 30.</citation>
    <PMID>22133470</PMID>
  </reference>
  <reference>
    <citation>Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987 Aug;13(2):110-7.</citation>
    <PMID>2887325</PMID>
  </reference>
  <reference>
    <citation>Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994 Mar 15;23(4):943-50.</citation>
    <PMID>8106700</PMID>
  </reference>
  <reference>
    <citation>Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May;25(6):1225-31.</citation>
    <PMID>7722114</PMID>
  </reference>
  <reference>
    <citation>Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994 Dec;24(7):1678-87.</citation>
    <PMID>7963115</PMID>
  </reference>
  <reference>
    <citation>Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995 Sep 15;92(6):1499-506.</citation>
    <PMID>7664433</PMID>
  </reference>
  <reference>
    <citation>Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8.</citation>
    <PMID>11386263</PMID>
  </reference>
  <reference>
    <citation>Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.</citation>
    <PMID>8614419</PMID>
  </reference>
  <reference>
    <citation>Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997 Feb 8;349(9049):375-80.</citation>
    <PMID>9033462</PMID>
  </reference>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.</citation>
    <PMID>23747642</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):361-2.</citation>
    <PMID>22828712</PMID>
  </reference>
  <reference>
    <citation>Liu M, Zhang D, Sun Y, Wang Y, Liu Z, Gu J. Liquid chromatographic-electrospray tandem mass spectrometric determination of bisoprolol in human plasma. Biomed Chromatogr. 2007 May;21(5):508-13.</citation>
    <PMID>17294507</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bisoprolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

